Talaris Therapeutics Inc - ESG Rating & Company Profile powered by AI
This ESG score for Talaris Therapeutics Inc indicates its transparency towards the UN SDGs. This article contains a questions and answers section about Talaris Therapeutics Inc. This assessment of Talaris Therapeutics Inc is assembled by All Street Sevva using proprietary AI.
Talaris Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.0; made up of an environmental score of 3.2, social score of 8.0 and governance score of 6.7.
6.0
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 623 | Paion AG | 6.1 | High |
| 623 | Valbiotis SA | 6.1 | High |
| 669 | Talaris Therapeutics Inc | 6.0 | High |
| 669 | Bachem Holding AG | 6.0 | High |
| 669 | Advaxis Inc | 6.0 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Talaris Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Talaris Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Talaris Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Talaris Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Talaris Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Talaris Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Talaris Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Talaris Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Talaris Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Talaris Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Talaris Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Talaris Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Talaris Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Talaris Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Talaris Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Talaris Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Talaris Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Talaris Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Talaris Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Talaris Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Talaris Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Talaris Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Talaris Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Talaris Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Talaris Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Talaris Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Talaris Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Talaris Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Talaris Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Talaris Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Talaris Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Talaris Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Talaris Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Talaris Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Talaris Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Talaris Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Talaris Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.